Q32 Bio (QTTB) Cash & Equivalents (2017 - 2026)

Q32 Bio's Cash & Equivalents history runs 10 years deep, the most recent figure standing at $50.8 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 22.5% year-over-year to $50.8 million in Q1 2026; TTM through Mar 2026 was $50.8 million, a 22.5% decrease from a year earlier, with the FY2025 full-year figure at $48.3 million, up 7364.76% from the prior year.
• Cash & Equivalents climbed to $50.8 million in Q1 2026 per QTTB's latest filing, from $48.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $248.1 million in Q1 2022 and bottomed at $647000.0 in Q4 2024.
• The 5-year median for Cash & Equivalents is $49.0 million (2025), against an average of $65.3 million.
• Across the five-year window, Cash & Equivalents sank 97.72% in 2023 and jumped 7364.76% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $34.0 million in 2022, then plunged by 83.38% to $5.6 million in 2023, then tumbled by 88.54% to $647000.0 in 2024, then soared by 7364.76% to $48.3 million in 2025, then increased by 5.08% to $50.8 million in 2026.
• Per Business Quant, the three latest QTTB Cash & Equivalents figures stand at $50.8 million (Q1 2026), $48.3 million (Q4 2025), and $49.0 million (Q3 2025).